Advanced Prostate Cancer VL

Looking Forward to the APCCC 2019 - Brenda Martone

Details
Alicia Morgans and Brenda Martone discuss the upcoming Advanced Prostate Cancer Consensus Conference (APCCC 2019). This global conference focuses on the grey areas where Level 1 Evidence is not available to guide treatment decisions in the clinic. Experts from around the globe will gather in Basel Switzerland from August 28 - August 31 to discuss areas of controversy in the treatment of prostate c...

Preview of the Advanced Prostate Cancer Consensus Conference 2019 (APCCC) - Silke Gillessen and Aurelius Omlin

Details
Silke Gillessen, MD and Aurelius Omlin, MD discuss the inception of the biennial Advanced Prostate Cancer Consensus Conference (APCCC) which will be held in Basel this August. The intent of the meeting is to drive international consensus on key areas of prostate cancer practice where there are no clear guidelines or level 1 evidence. 75% of the panelists must agree on each topic to reach a consens...

Real-World Evaluation of Disparities in Prostate Cancer Outcomes - Daniel Spratt

Details
Daniel Spratt and Todd Morgan discuss the analysis of why is it that black men appear to be dying more often of prostate cancer. They review their approach to understanding more about this real-world question. Biographies: Todd Matthew Morgan MD Associate Professor Specialties: Urology Area of Practice: Prostate Cancer, including robotic prostatectomy and active surveillance; Bladder Cancer, inclu...

Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines - Oliver Sartor

Details
Oliver Sartor, MD discusses his contributions to the recent publication in JAMA Oncology on the prevalence of germline variants in prostate cancer and the implications for genetic testing guidelines. 3600 patients had various forms of germiline genetic testing performed and were available for this analysis. In the dataset, 17% of patients had germline variants and 30% of those were BRCA1/BRCA2. In...

Biomarkers Across the Spectrum of Prostate Cancer- Anis Hamid and Chris Sweeney

Details
Anis Hamid and Chris Sweeney discuss their recent work studying biomarkers across the full spectrum of prostate cancer. Based on preclinical studies we understand that aggressive disease lies in the tumor genome and we see recurrent losses of certain genes in both early and advanced prostate cancer. The classic tumor suppressors that are commonly mutated across cancers, including prostate cancer,...

Integrating Genomics into Localized Prostate Cancer - Todd Morgan and Daniel Spratt

Details
Daniel Spratt and Todd Morgan discuss the role of genomics in localized prostate cancer from the perspective of the radiation oncologist and the urologist. Based on the MUSIC registry, which represents over 90% of the urology practices across Michigan, they reveal that most of the prostate cancer patients are not receiving genomic profiling. Drs. Spratt and Morgan review each of the genomic tests...

Precision Oncology: The PCF - Veterans Affairs (VA) Initiative - Bruce Montgomery

Details
Bruce Montgomery shares an update on the PCF - VA research Initiative on precision oncology in prostate cancer. Prostate Cancer Foundation has provided a $50 million dollar contribution to this VA specific prostate cancer effort. Bruce and Chuck Ryan discuss the developments to date and the future plans. Biographies: Bruce Montgomery, MD Board-certified oncologist, clinical director of Genitourina...

Urologists Perspectives on Prostate Cancer Presentations from ASCO GU 2019 - Edward Schaeffer

Details
Alicia Morgans discusses key take home messages from the prostate cancer presentations from ASCO GU 2019 with Edward Schaeffer. He highlighted presentations on the diagnosis and treatment of prostate cancer across the disease continuum, developing tools for shared decision making between the physican and patient, the pros and cons of screening for prostate cancer and both the ARAMIS and the ARCHES...

Practice Patterns of Active Surveillance in Prostate Cancer - Matt Cooperberg

Details
Alicia Morgans and Matt Cooperberg discuss the current state of contemporary active surveillance and efforts to standardize strategies nationwide. This conversation also includes discussion on informed decision making and practice patterns of active surveillance and how to tailor based on biology and genetics Biographies: Matthew Cooperberg, MD, MPH, FACS, Associate Professor, Department of Urolog...

Challenges in the Treatment of Localized Prostate Cancer - Srikala Sridhar

Details
Kala Sridhar and Alicia Morgans share in a discussion on challenges and opportunities in the treatment of localized prostate cancer from the viewpoint of a medical oncologist. Conversation includes approaches for optimizing systemic therapy in localized disease and new hormonal agents, and the ICECAP initiative. Biographies: Srikala (Kala) Sridhar MD, MSc, FRCPC Medical Advisory and Research Board...